Cardlytics, Inc.
DE ˙ DB ˙ US14161W1053
0,45 € ↓ -0,04 (-8,23%)
2026-06-05
DEL PRIS
SecurityDE:CYX / Cardlytics, Inc.
InstitutionBnp Paribas Arbitrage, Sa
Latest Disclosed Ownership20 shares
Latest Disclosed Value $ 21
Bnp Paribas Arbitrage, Sa ownership in CYX / Cardlytics, Inc.

On May 12, 2026 - Bnp Paribas Arbitrage, Sa filed a 13F-HR form disclosing ownership of 20 shares of Cardlytics, Inc. (DE:CYX) valued at $15 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 20 shares of Cardlytics, Inc.. The current value of the position is $9 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F Cardlytics Equity 14161W105 20 0 0.00 0 0.0000
2026-02-10 2025-12-31 13F Cardlytics Equity 14161W105 20 -218 -91.60 0 0.0000
2025-11-13 2025-09-30 13F Cardlytics Equity 14161W105 238 -460 -65.90 1 -100.00 0.0000
2025-08-14 2025-06-30 13F Cardlytics Equity 14161W105 698 -42,304 -98.38 1 -98.72 0.0000
2025-05-14 2025-03-31 13F Cardlytics Equity 14161W105 43,002 1,095 2.61 78 -49.68 0.0000
2025-02-14 2024-12-31 13F Cardlytics Equity 14161W105 41,907 22,162 112.24 155 146.03 0.0001
2024-11-13 2024-09-30 13F Cardlytics Equity 14161W105 19,745 4,796 32.08 63 -48.36 0.0000
2024-08-13 2024-06-30 13F Cardlytics Equity 14161W105 14,949 -6,267 -29.54 123 -60.26 0.0001
2024-05-01 2024-03-31 13F Cardlytics Equity 14161W105 21,216 -9,334 -30.55 307 9.25 0.0003
2024-02-14 2023-12-31 13F/A-2 Cardlytics Equity 14161W105 30,550 4,246 16.14 281 -35.25 0.0003
2024-02-07 2023-12-31 13F/A-1 Cardlytics Equity 14161W105 30,550 4,246 281 0.0000
2024-02-07 2023-12-31 13F Cardlytics Equity 14161W105 30,550 281
2023-11-14 2023-09-30 13F Cardlytics Equity 14161W105 26,304 17,442 196.82 434 675.00 0.0006
2023-08-09 2023-06-30 13F Cardlytics Equity 14161W105 8,862 -13,338 -60.08 56 -25.33 0.0001
2023-05-12 2023-03-31 13F CARDLYTICS EQUITY 14161W105 22,200 -20,462 -47.96 75 -69.51 0.0001
2023-02-14 2022-12-31 13F Cardlytics Equity 14161W105 42,662 26,590 165.44 247 62.91 0.0004
2022-11-16 2022-09-30 13F/A-1 Cardlytics Equity 14161W105 16,072 6,234 63.37 151 -31.05 0.0002
2022-11-15 2022-09-30 13F Cardlytics Equity 14161W105 16,072 6,234 151 0.0000
2022-08-12 2022-06-30 13F Cardlytics Equity 14161W105 9,838 7,026 249.86 219 42.21 0.0003
2022-05-18 2022-03-31 13F/A-1 Cardlytics Equity 14161W105 2,812 -4,066 -59.12 155 -66.08 0.0002
2022-02-09 2021-12-31 13F CARDLYTICS EQUITY 14161W105 6,878 839 13.89 455 -10.28 0.0006
2021-11-16 2021-09-30 13F/A-1 CARDLYTICS EQUITY 14161W105 6,039 4,865 414.40 507 239.60 0.0007
2021-11-12 2021-09-30 13F CARDLYTICS EQUITY 14161W105 6,189 5,015 437 0.0000
2021-08-10 2021-06-30 13F CARDLYTICS EQUITY 14161W105 1,174 -2,680 -69.54 149 -64.69 0.0002
2021-05-07 2021-03-31 13F CARDLYTICS EQUITY 14161W105 3,854 -1,070 -21.73 423 -39.89 0.0006
2021-02-10 2020-12-31 13F CARDLYTICS EQUITY 14161W105 4,924 -1,265 -20.44 703 61.01 0.0013
2020-10-30 2020-09-30 13F CARDLYTICS EQUITY 14161W105 6,189 5,117 477.33 437 481.33 0.0006
2020-08-06 2020-06-30 13F CARDLYTICS EQUITY 14161W105 1,072 -3,365 -75.84 75 -51.61 0.0001
2020-05-13 2020-03-31 13F CARDLYTICS EQUITY 14161W105 4,437 -156,908 -97.25 155 -98.47 0.0003
2020-02-12 2019-12-31 13F CARDLYTICS EQUITY 14161W105 161,345 159,426 8,307.76 10,142 15,746.88 0.0185
2019-11-07 2019-09-30 13F CARDLYTICS EQUITY 14161W105 1,919 1,245 184.72 64 276.47 0.0001
2019-07-30 2019-06-30 13F CARDLYTICS EQUITY 14161W105 674 -594 -46.85 18 -15.00 0.0000
2019-04-25 2019-03-31 13F CARDLYTICS EQUITY 14161W105 1,268 1,178 1,308.89 21 2,051.08 0.0000
2019-02-12 2018-12-31 13F CARDLYTICS EQUITY 14161W105 90 -89 -49.72 1 -100.00 0.0000
2018-11-07 2018-09-30 13F CARDLYTICS EQUITY 14161W105 179 -42 -19.00 4 0.00 0.0000
2018-07-25 2018-06-30 13F CARDLYTICS EQUITY 14161W105 221 -716 -76.41 5 -69.23 0.0000
2018-05-11 2018-03-31 13F CARDLYTICS EQUITY 14161W105 937 937 14 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.